UC San Francisco Cell Therapy Raises Hope for Severe Human Forms
Epilepsy that does not respond to drugs can be halted in adult mice by transplanting a specific type of cell into the brain, UC San Francisco researchers have discovered, raising hope that a similar treatment might work in severe forms of human epilepsy.
UCSF scientists controlled seizures in epileptic mice with a one-time transplantation of medial ganglionic eminence (MGE) cells, which inhibit signaling in overactive nerve circuits, into the hippocampus, a brain region associated with seizures, as well as with learning and memory. Other researchers had previously used different cell types in rodent cell transplantation experiments and failed to stop seizures.
Cell therapy has become an active focus of epilepsy research, in part because current medications, even when effective, only control symptoms and not underlying causes of the disease, according to Scott C. Baraban, PhD, who holds the William K. Bowes Jr. Endowed Chair in Neuroscience Research at UCSF and led the new study. In many types of epilepsy, he said, current drugs have no therapeutic value at all.
“Our results are an encouraging step toward using inhibitory neurons for cell transplantation in adults with severe forms of epilepsy,” Baraban said. “This procedure offers the possibility of controlling seizures and rescuing cognitive deficits in these patients.”
The findings, which are the first ever to report stopping seizures in mouse models of adult human epilepsy, will be published online May 5 in the journal Nature Neuroscience.
During epileptic seizures, extreme muscle contractions and, often, a loss of consciousness can cause seizure sufferers to lose control, fall and sometimes be seriously injured. The unseen malfunction behind these effects is the abnormal firing of many excitatory nerve cells in the brain at the same time.
In the UCSF study, the transplanted inhibitory cells quenched this synchronous, nerve-signaling firestorm, eliminating seizures in half of the treated mice and dramatically reducing the number of spontaneous seizures in the rest. Robert Hunt, PhD, a postdoctoral fellow in the Baraban lab, guided many of the key experiments.
In another encouraging step, UCSF researchers reported May 2 that they found a way to reliably generate human MGE-like cells in the laboratory, and that, when transplanted into healthy mice,the cells similarly spun off functional inhibitory nerve cells. That research can be found online in the journal Cell Stem Cell.
In many forms of epilepsy, loss or malfunction of inhibitory nerve cells within the hippocampus plays a critical role. MGE cells are progenitor cells that form early within the embryo and are capable of generating mature inhibitory nerve cells called interneurons. In the Baraban-led UCSF study, the transplanted MGE cells from mouse embryos migrated and generated interneurons, in effect replacing the cells that fail in epilepsy. The new cells integrated into existing neural circuits in the mice, the researchers found.
“These cells migrate widely and integrate into the adult brain as new inhibitory neurons,” Baraban said. “This is the first report in a mouse model of adult epilepsy in which mice that already were having seizures stopped having seizures after treatment.”
The mouse model of disease that Baraban’s lab team worked with is meant to resemble a severe and typically drug-resistant form of human epilepsy called mesial temporal lobe epilepsy, in which seizures are thought to arise in the hippocampus. In contrast to transplants into the hippocampus, transplants into the amygdala, a brain region involved in memory and emotion, failed to halt seizure activity in this same mouse model, the researcher found.
The Latest Bing News on:
Epilepsy
- New purple truck promotes epilepsy awareness in honour of daughteron April 22, 2024 at 11:55 pm
For Queensland based transport business, R & K Bulk Haulage, several trucks serve as moving billboards for causes close to the owners’ hearts.
- Inpatient rehab program aids adaptation to epilepsy diagnosison April 22, 2024 at 10:00 am
An inpatient, epilepsy-related rehabilitation program shows lasting effects on several aspects of adaptation to epilepsy and quality of life, according to a study published April 16 in Epilepsia.
- Kaleida Epilepsy Centers Achieve Level 4 NAECon April 22, 2024 at 8:08 am
Both the adult and pediatric Kaleida Health epilepsy centers have achieved accreditation as Level 4 NAEC (National Association of Epilepsy Centers) centers.
- Global Epilepsy Treatment Drugs Market Size To Exceed USD 12.1 Billion By 2033 | CAGR Of 4.36%on April 22, 2024 at 1:00 am
The Global Epilepsy Treatment Drugs Market Size was Valued at USD 7.9 Billion in 2023 and the Worldwide Epilepsy Treatment Drugs Market Size is Expected to Reach USD 12.1 Billion by 2033, according to ...
- Breaking Boundaries in Pediatric Neurology: HP Ghosh Hospital Leads the Way in Childhood Epilepsy Treatmenton April 21, 2024 at 10:01 pm
However, with proper treatment, this condition is entirely manageable. Recognizing the gravity of such ailments, HP Ghosh Hospital has pioneered efforts to ensure accessible treatment for the general ...
- Hidden Brain Region May Unlock New Epilepsy Treatmenton April 19, 2024 at 8:55 am
A new study offers an explanation and suggests a more effective approach to treatment of epilepsy. They found a previously overlooked region of the hippocampus, the fasciola cinereum, appears to be ...
- Epilepsy procedure helping South Florida teen improve quality of lifeon April 18, 2024 at 6:46 pm
An epilepsy diagnosis affects one in every 26 people. Jose Saenz was diagnosed with epilepsy as a child. Now a teenager, he has a new medical device that helps him manage his seizures and improve his ...
- Epilepsy Newson April 17, 2024 at 5:00 pm
Nov. 30, 2023 — Slow waves that usually only occur in the brain during sleep are also present during wakefulness in people with epilepsy and may protect against increased brain excitability ...
- Harvard Health Publishing And 3 More Doctors Weigh In On: What Can Trigger Epilepsy?on April 17, 2024 at 2:28 pm
Answered by Dr. Howard E. Lewine M.D. Chief Medical Editor, Harvard Health Publishing · 40 years of experience · USA Many conditions can affect the brain and trigger a seizure, including:, Brain ...
- Surgery targeting brain region may relieve tough-to-treat epilepsyon April 17, 2024 at 6:05 am
Some people with tough-to-treat epilepsy might benefit if doctors target a brain region newly linked to the disorder, a new study suggests. Seizures declined by 83% after a patient underwent surgery ...
The Latest Google Headlines on:
Epilepsy
[google_news title=”” keyword=”Epilepsy” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
The Latest Bing News on:
Cell therapy
- Adicet Bio Highlights Preclinical Data Supporting IND Readiness for ADI-270 in an Oral Presentation at the American Society of Gene and Cell Therapy (ASGCT) 27th Annual Meetingon April 22, 2024 at 5:30 pm
Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimm ...
- Regeneron to Highlight Advances in Genetic Medicine Research at American Society of Gene and Cell Therapy (ASGCT)on April 22, 2024 at 4:17 pm
Oral presentations include updated results from clinical study of otoferlin gene therapy DB-OTO demonstrating restoration in children with ...
- GeneFab Announces Two Presentations at the American Society of Gene & Cell Therapy (ASGCT) Annual Meeting 2024on April 22, 2024 at 1:30 pm
Two accepted abstracts highlight innovative methods for gene expression regulation – – GeneFab’s synthetic biology capabilities and Advanced Therapies offerings enable development of affordable ...
- With $380M deal, Bristol Myers Squibb ups the ante with cell therapy manufacturer Cellareson April 22, 2024 at 8:10 am
Bristol Myers Squibb was the first major biopharma company to take notice of innovative cell therapy contract manufacturer Cellares, participating to a $255 million series C funding round in August | ...
- Review Finds Anti-BCMA CAR T-Cell Therapy Effective in Patients With MMon April 22, 2024 at 7:11 am
A new meta-analysis of chimeric antigen receptor (CAR) T-cell therapy in patients with multiple myeloma (MM) suggests the treatment has a strong rate of efficacy and that adverse events (AEs) ...
- Passage Bio to Present at Chardan’s 8th Annual Genetic Medicines and Cell Therapy Manufacturing Summiton April 22, 2024 at 4:21 am
A live webcast of the event will be available on the Investors & Media section of Passage Bio’s website at investors.passagebio.com. A replay of the presentation will be available for 30 days ...
- 5 Cell and Gene Therapy Decisions to Watch in 2024on April 21, 2024 at 9:03 pm
All signs point to 2024 surpassing 2023 as a landmark year for cell and gene therapy,” David Barrett, CEO of the American Society of Gene & Cell Therapy (ASGCT), told BioSpace. The first approval this ...
- Cellares unveils first-of-its-kind cell therapy manufacturing toolon April 19, 2024 at 10:47 am
Cellares unveiled Cell Q Thursday, the first automated quality control (QC) workcell for cell therapy manufacturing. According to the company, Cell Q complements its Cell Shuttle Platform by ...
- Novel cell therapy treatments offer promise to immune-compromised childrenon April 18, 2024 at 10:03 am
In a first-of-its-kind clinical trial, researchers found that intravenous therapies made from virus-specific T-cells (VST) can effectively treat immunocompromised pediatric patients, far surpassing ...
- Century secures $60m in stock sale and buys preclinical cell therapy biotechon April 12, 2024 at 10:09 am
For the acquisition, Century will pay an upfront cost of $35m in cash and shares, along with a $10m one-time milestone payment. The company will gain three preclinical allogeneic induced pluripotent ...
The Latest Google Headlines on:
Cell therapy
[google_news title=”” keyword=”Cell therapy” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]